Siddharth Mittal Appointed as Managing Director & CEO of Syngene International
Syngene International announced that Siddharth Mittal has assumed the role of Managing Director and Chief Executive Officer of the Company, effective 1 July 2026.
Pharma
Symeres and Axxam Unite Drug Discovery Platforms Under Single Scientific Chief
Russell Thomas, who has held senior roles at both organisations, takes on the joint CSO position as Symeres and Axxam push to offer clients a single pipeline spanning target screening to IND-ready drug candidates.
Former Bachem Executive Torsten Woehr to Become CEO of Rentschler
Rentschler Biopharma has appointed Torsten Woehr as Chief Executive Officer (CEO), effective August 1, 2026.
Adragos and Towa to Produce 1.5 Billion Tablets a Year
CDMO Adragos Pharma Kawagoe and Towa Pharmaceutical have agreed to a manufacturing partnership that will nearly triple solid-dosage capacity, shoring up Japan's fragile generics supply chain.
Lonza Expands Visp Site to Meet Demand in ADCs
Lonza to expand payload-linker manufacturing capacity in Visp (CH) to support the rapidly growing antibody-drug conjugate (ADC) market.
Digitalization as a Strategic Lever in R&D
Digital Innovation: a key driver of competitiveness and sustainability across the pharmaceutical industry.
Elevating AI-Driven Discovery: Simplifying Complexity with CDD Vault
Drug discovery generates enormous amounts of data, but turning it into meaningful insight is a major challenge.
Pharma 4.0: Big Promises, Poor Data - What’s Going Wrong?
Pharma 4.0 is high on every strategic agenda. Yet many struggle to turn digital ambitions into measurable results. Projects stall, systems don’t align, and valuable insights remain locked in fragmented data structures.
The Hidden Cost of How Chemical Companies Experiment
Smart Experimentation - why the combination of Design of Experiments and Bayesian Optimization with intuitive analytics is the most important productivity lever your R&D organization isn't using
Closing the Gap Between Lab and Production
Shorter development cycles and complex active ingredients are demanding integrated solutions. Guided by the principle "Together – from lab to production," Fette Compacting positions its R&D Solutions as a partnership.
AI as a Game Changer
How Artificial Intelligence is transforming the work of biotech and pharma companies.
Lonza Issues License to Antharis Therapeutics for ADCs
Lonza and Antharis Therapeutics announced an exclusive, target-specific licensing agreement to develop novel dual-payload ADCs targeting gastrointestinal (GI) cancers.
Recipharm Expands US Sterile Fill and Finish Capabilities
Recipharm announced a multi-million-dollar investment in its US operations, strengthening its ability to support pharma and biotech companies with advanced sterile fill and finish services.
Chiesi Group Acquires KalVista Pharmaceuticals for $1.9 Billion
Chiesi Group has completed its acquisition of KalVista Pharmaceuticals, marking the Italian biopharmaceutical group's largest deal to date.
Siegfried Inaugurates Pharma API plant in Minden
Siegfried has inaugurated a new large-scale API production facility at its German site in Minden.
GSK Strikes $10.6 Billion Deal for Nuvalent in One of Pharma's Biggest Oncology Acquisitions of 2026
GSK has agreed to acquire US clinical-stage oncology specialist Nuvalent for $10.6 billion, its largest deal in years, to accelerate entry into lung cancer and boost growth through the dolutegravir patent cliff.
Axplora Repositions European Site on High-Potency Drugs as India Takes Over UDCA Production
Axplora is repositioning its Italian Farmabios site on high-potency APIs as UDCA production moves to its FDA-approved Vizag facility in India, consolidating supply and scaling for global demand.
Eli Lilly and Boehringer Ingelheim Cancel Investments
A clear signal to Berlin: the pharmaceutical companies Eli Lilly and Boehringer Ingelheim are canceling planned investments in Germany.
Sygnature Discovery Collaborates with DaltonTx to Advance AI-enabled Drug Discovery
Sygnature Discovery has partnered with AI firm DaltonTx to sharpen its drug discovery pipeline, bringing faster medicinal chemistry decisions and tighter data privacy to its CRO offering.
Northway Biotech Invests €61 Million in Vilnius Cell Therapy Manufacturing Center
Northway Biotech is finalizing the Baltic region's most advanced cell therapy center — a 3,500 m² facility at Vilnius City Innovation Industrial Park, set to open Q3 2025.
CordenPharma Acquires AmbioPharm to Expand Peptide API Capacity
Acquisition strengthens US peptide manufacturing capabilities and broadens global expertise in complex peptide APIs
Catalent and Elpida Therapeutics Join Forces for Gene Therapy Scale-Up
Catalent partners with non-profit Elpida Therapeutics to support late-phase AAV manufacturing for a rare neurological gene therapy, securing exclusive rights across Elpida's broader AAV pipeline.
Alcami Completes Tjoapack Acquisition to Bolster Global Packaging Scale
Alcami completes its acquisition of Tjoapack, creating a 1,400-strong CDMO with over one million square feet of operations across the US and the Netherlands, adding European packaging scale and QP release services.
Hongene Backs SiranBio's RNAi Pipeline with Advanced CDMO Support
Hongene Biotech delivers end-to-end CDMO services for SiranBio's dual-target siRNA hepatitis B candidate, from raw materials through cGMP manufacturing, highlighting its capabilities in oligonucleotide therapeutics.
Bristol Myers Squibb Bolsters Oncology Pipeline with Lonza Licensing Agreement
Bristol Myers Squibb licenses Lonza's SYNtecan linker-payload platform to advance an undisclosed ADC target, with Lonza eligible for upfront payments, milestones and royalties on resulting products.
Piramal Pharma Solutions Expands CDMO Capabilities at Michigan Facility
Piramal Pharma Solutions opens a new payload-linker suite in Michigan as part of a $90 million US investment plan, bolstering its ADC manufacturing capabilities across sites in Riverview and Lexington.
Lilly Deepens Lebanon Campus Investment with $4.5 Billion Commitment
Eli Lilly adds $4.5 billion to its Indiana manufacturing programme, funding a new genetic medicine facility and expanded API capacity at Lebanon, taking its total US investment since 2020 past $50 billion.
Symeres Appoints Henning Steinhagen as CEO
Symeres, a transatlantic CRDMO for drug discovery and development, announced the appointment of Henning Steinhagen as Chief Executive Officer.
Takeda Invests in Climate-Neutral Energy Supply
Takeda has officially commissioned a new photovoltaic system at its production site in Oranienburg near Berlin.
Mastering Modified Release: The Pellet-Based Approach
Explore how pellet-based systems can de-risk development and scale-up of robust modified-release formulations across the product lifecycle.
Siegfried Secures Antitrust Green Light for US and Australia Drug‑Substance Site Takeover
All closing conditions satisfied for the acquisition of three small molecule sites in the US and Australia; closing to occur as of May 1, 2026. Adds highly demanded US-based manufacturing capacity to Siegfried's network.
Resilience by Design: How Leaders Prepare Supply Chains for an Evolving Landscape
In this CHEManager Leaders & Motivators interview, Frank Romanski, Lonza Capsugel, reflects on how strategy becomes execution and what resilience demands from teams,
India’s CDMO Strength: Powering Global Chemical Innovation
India’s CDMO sector is rapidly advancing: stronger R&D, complex chemistry, digitalization, and efficiency gains. Astec boosts this with new R&D centers, automation, and global‑standard operations.
Henrik Krüpper Becomes New CEO of Unither Pharmaceuticals
Unither Pharmaceuticals welcomes Henrik Krüpper as Chief Executive Officer of the Group, starting May 4.
AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus
The investment, its largest since its inception, demonstrates continued progress against AbbVie's $100 billion commitment to US R&D and capital investments, including manufacturing, over the next decade.
